Literature DB >> 16679004

The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion.

Miriam Schneider1, Michael Koch.   

Abstract

We here report on behavioral effects of neonatal medial prefrontal cortex (mpfc) lesions in rats, followed by chronic peripubertal treatment with the cannabinoid full agonist WIN 55,212-2 (WIN). Rat pups received excitotoxic lesions of the mpfc on postnatal day (pd) 7. Chronic WIN (1.2 mg/kg) treatment was extended throughout the rats' puberty (pd 40-65). All animals were tested as juveniles and adults for short-term memory functioning using the spontaneous object recognition test, and for locomotor activity in an open field. Lesioned rats showed impairments in recognition memory when tested prepubertally. Postpubertal testing of lesioned animals revealed a persisting recognition memory impairment that was intensified by pubertal WIN treatment. Chronic WIN treatment during puberty also affected recognition memory in sham-lesioned rats and controls. No effects on locomotor activity of either neonatal lesion or pubertal cannabinoid treatment were found. This study shows that behavioral deviations induced by neonatal mPFC lesions can be exacerbated by pubertal chronic cannabinoid treatment, leading to long-lasting impairments of mnemonic short-term information processing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679004     DOI: 10.1016/j.euroneuro.2006.03.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  23 in total

1.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

2.  Of rats and schizophrenia.

Authors:  Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

Review 3.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.

Authors:  Daniel T Malone; Matthew N Hill; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 5.  Consequences of adolescent use of alcohol and other drugs: Studies using rodent models.

Authors:  Linda Patia Spear
Journal:  Neurosci Biobehav Rev       Date:  2016-07-30       Impact factor: 8.989

Review 6.  Framework for sex differences in adolescent neurobiology: a focus on cannabinoids.

Authors:  Maria-Paz Viveros; Eva M Marco; Meritxell López-Gallardo; Luis Miguel Garcia-Segura; Edward J Wagner
Journal:  Neurosci Biobehav Rev       Date:  2010-09-30       Impact factor: 8.989

7.  Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.

Authors:  Hila Abush; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2013-02-20       Impact factor: 7.853

Review 8.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

9.  Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.

Authors:  Ana Belen Lopez-Rodriguez; Alvaro Llorente-Berzal; Luis M Garcia-Segura; Maria-Paz Viveros
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Neurocognition in college-aged daily marijuana users.

Authors:  Mary P Becker; Paul F Collins; Monica Luciana
Journal:  J Clin Exp Neuropsychol       Date:  2014-03-12       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.